Partnership to Improve Patient Care

  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Action Center
    • Value Our Health
    • International
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • News
    • Press Releases
    • PIPC in the News
    • PIPC Weekly Update
    • PIPC Patients' Blog
    • Chairman's Corner
    • The Data Mine
  • Events
    • MFN/IPI Webinar 2025
    • QALY Panel
    • QALY Briefing
    • Past Webinars >
      • Discrimination & Health Care
      • C & GT Webinar
      • ICER COVID Webinar
      • Value Our Health Briefing
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010
  • Home
  • About
    • Mission and Priorities
    • Meet the Chairman
    • Steering Committee
    • PIPC Member List
    • Contact
  • The Issues
    • Action Center
    • Value Our Health
    • International
    • Where We Stand
    • Value Assessment Frameworks
    • Engaging Patients in Value-Based Payment
    • Patient-Centeredness in Research
  • Resources
    • Advocacy
    • Letters and Comments
    • PCORI Meeting Transcripts
    • Polling
    • Roundtables
    • White Papers
  • News
    • Press Releases
    • PIPC in the News
    • PIPC Weekly Update
    • PIPC Patients' Blog
    • Chairman's Corner
    • The Data Mine
  • Events
    • MFN/IPI Webinar 2025
    • QALY Panel
    • QALY Briefing
    • Past Webinars >
      • Discrimination & Health Care
      • C & GT Webinar
      • ICER COVID Webinar
      • Value Our Health Briefing
      • ICER SCD Webinar
      • VOH Sickle Cell Webinar
      • Rare Disease Webinar
      • QALY Webinar
      • PCORI Advocacy Webinar
      • APM Webinar
      • Patient Empowerment Webinar
      • Value Assessments Briefing
    • Past PIPC Forums >
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
      • 2011
      • 2010

The PIPC Blog

PIPC Patient Blog: Seeing the Promise in Gene Therapy

1/12/2018

 
Picture
By: Janni Lehrer-Stein

​A 10-year-old girl sees her mother’s face for the first time. An 11-year-old boy races through the aisles of Target, marveling at toys he never knew existed. Both children had mere glimmers of vision, and were destined to lose even that because of an inherited eye disease with no treatment or cure. But thanks to the miracles of modern-day medicine, what was once only possible in science fiction novels is now becoming reality. 

In December, the FDA approved the first gene therapy for any inherited disease — this one being for eyesight, which is historic news for medical science. It was particularly encouraging for people with inherited rare diseases.  For people with vision loss caused by a mutation to the RPE65 gene — which the new gene therapy corrects — this one-time treatment will be forever life-changing.  As a member of the Foundation Fighting Blindness, a non-profit organization that has strived for almost fifty years to drive research to treat and cure inherited retinal disease, I have eagerly awaited this moment.
 
Spark Therapeutics — the company that conducted the clinical trials that showed the treatment’s efficacy and that now has the approval to market it — and the many researchers who made this breakthrough possible, are to be congratulated. But, the next question inevitably looms: how do we ensure patient access to the treatment?
 
Adjustments to traditional insurance coverage will be needed considering the unique feature of this treatment; it is a one-time application in each eye that results in significant positive outcomes.  To reach patients and change lives for the better will require government, industry, patients and consumers to work together to develop a new framework for covering this kind of drug therapy.

In that spirit, I was relieved to hear last week that the manufacturer had announced a series of innovative strategies to facilitate patient access to the treatment, thereby seeking to reduce the risk and financial burden to treatment centers, insurance companies, and patients.  Harvard Pilgrim and Express Scripts have already agreed to partner on these new model payment programs.  Additionally, the Center for Medicaid and Medicare Services (CMS) is exploring strategies to offer payers the option to spread payments for certain treatments across multiple years.
 
Alternative payment models such as outcomes-based rebate models are aligned with a pay-for-performance approach, requiring the manufacturer to stand behind the efficacy and durability of the treatment — in this case, a one-dose treatment. And by embracing the principles of paying for “value,” both public and private payers are laying the necessary foundation for patient access in a world of 21st century cures.
 
The health science industry is making great strides toward developing cures for once incurable diseases.  That includes preventions and cures for inherited retinal diseases that for me and millions of people like me, robbed us of our sight.  An organization I’m proud to be a part of, the Foundation Fighting Blindness, has helped drive such research in the inherited blindness space.  But any new treatment is only as good as a patient’s access to it.
 
Spark Therapeutics, by thinking outside the box, has created an exciting new model of cost and risk sharing between the drug developer, treatment centers, and insurance companies.  If embraced by additional industry leaders, it will propel current research and will greatly enhance patient access to breakthrough treatments.
 
So bravo to the Foundation Fighting Blindness and to the scores of scientists who have worked so hard — not only to develop the first gene therapy treatment for inherited blinding disease, but also for the potential for this research to reach beyond treatments for blindness, with translational impacts on other inherited diseases. Further, kudos to Spark Therapeutics and its payer partners for understanding the need to both develop innovative treatment and to break down barriers to access for patients. And of course, my thanks to the community of physicians, scientists and our government stakeholders who are needed to work alongside manufacturers, advocates, payers, and others to ensure development of and access to life-enhancing treatment, in this case a ground-breaking treatment to restore vision!
 
About the Author
Janni Lehrer-Stein is a disability rights advocate and former attorney, a graduate of Yale University and the University of Toronto Law School. She was appointed by President Barack Obama and confirmed by the United States Senate to serve on the National council on Disability, for which she served two terms from 2011-2016. Currently, Janni is a member of the board of Directors of the Foundation Fighting Blindness, Disability Rights Advocates, and the National Academies of 
patient_blog_gene_therapy.pdf
File Size: 135 kb
File Type: pdf
Download File


Comments are closed.

    Topics

    All
    Alternative Payment Models
    Chairman's Corner
    Patient Centered Research
    PIPC In The News
    PIPC Patient Blog
    PIPC Weekly Update
    Press Releases
    The Data Mine
    Value Frameworks

    Archives

    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    May 2024
    April 2024
    March 2024
    February 2024
    January 2024
    December 2023
    November 2023
    October 2023
    September 2023
    August 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    April 2013
    March 2013
    December 2012
    November 2012
    February 2012
    September 2011
    August 2011
    July 2011
    May 2011
    March 2011
    November 2010
    October 2010
    September 2010
    August 2010
    April 2010
    March 2010
    February 2010
    December 2009
    September 2009
    July 2009
    June 2009
    May 2009
    February 2009
    January 2009
    December 2008

Powered by Create your own unique website with customizable templates.